Abstract
Background A recent hypothesis postulates the existence of an “immune-metabolic depression” (IMD) dimension characterized by metabolic dysregulations. Combining data on metabolomics and depressive symptoms, we aimed to identify depressions associated with an increased risk of adverse metabolic alterations.
Method Clustering data were from 1094 individuals with current major depressive disorder and measures of 149 metabolites from a 1H-NMR platform and 30 depressive symptoms (IDS-SR30). Canonical correlation analyses (CCA) were used to identify main independent metabolite-symptom axes of variance. Then, for the replication, we examined the association of the identified dimensions with metabolites from the same platform and cardiometabolic endpoints in an independent population-based cohort (n=6572).
Results CCA identified an overall depression dimension and a dimension resembling IMD, in which symptoms such as sleeping too much, increased appetite, and low energy level had higher relative loading. In the independent sample, the overall depression dimension was associated with lower levels of metabolites linked to cardiometabolic risk, such as HOMA-1B −0.09 (95% CI:-0.13--0.06), and visceral adipose tissue −0.15 cm2 (95% CI:-0.20--0.10). In contrast, the IMD dimension was associated with well-known adverse cardiometabolic metabolites such as higher visceral adipose tissue 0.11 cm2 (95% CI:0.06-0.16), HOMA-1B 0.08 (95% CI: 0.05-0.12), and lower HDL levels −0.04 mmol/L (95% CI:-0.07--0.01).
Conclusions Combining metabolomics and clinical symptoms we identified a replicable depression dimension associated with adverse metabolic alterations, in line with the IMD hypothesis. Patients with IMD may be at higher cardiometabolic risk and may benefit from specific treatment targeting underlying metabolic dysregulations.
Competing Interest Statement
Dennis Mook-Kanamori reports personal fees from Metabolon, Inc, outside the submitted work, and Brenda Penninx reports grants from Jansen Research and Development, LLC, and grants from Boehringer Ingelheim, outside the submitted work. All other co-authors declared no conflict of interest.
Funding Statement
NESDA The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organization for Health Research and Development (ZonMw, grant number: 10‐000‐1002) and financial contributions by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Rob Giel Onderzoekscentrum). NEO study The NEO study is supported by the participating Departments, Division, and Board of Directors of the Leiden University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative Medicine. DOM-K is supported by Dutch Science Organization (ZonMW-VENI Grant No. 916.14.023).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research protocol of NESDA was approved by the medical ethical committees of the following participating universities: Leiden University Medical Center (LUMC), Vrije University Medical Center (VUMC), and University Medical Center Groningen (UMCG). The NEO study was approved by medical ethics committee of Leiden University Medical Center (LUMC). All participants gave written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are not publicly available
